Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CHLSN antisense RNA 1 (CHLSN-AS1)
- Target
- CHLSN-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA
01
Overview
CHLSN antisense RNA 1 (CHLSN-AS1), also known as AC091729.7, is a long non-coding RNA (lncRNA) classified as an antisense RNA. It is upregulated in sinonasal squamous cell carcinoma and promotes tumor cell proliferation, migration, and invasion. Functionally, it binds to and regulates the protein SRSF2, a serine/arginine-rich splicing factor, thus contributing to oncogenic processes. Knockdown of CHLSN-AS1 significantly inhibits tumor growth in experimental models, and its expression levels correlate with patient prognosis, suggesting that it serves as both a biomarker and a potential therapeutic target in sinonasal squamous cell carcinoma. No direct interacting drugs or therapies are currently reported.
- Other names
- AC091729.7
02
Mechanism of action
Not established for drugs; mechanistically, acts through binding to and regulating serine/arginine rich splicing factor 2 (SRSF2) for oncogenic function
03
Biological functions
Regulation of gene expressionPromotion of cell proliferationPromotion of cell migrationPromotion of cell invasion
04
Disease associations
Cancer (specifically sinonasal squamous cell carcinoma)
05
Safety considerations
Not established; potential concern due to cancer association if targeted therapeutically
06
Biomarkers
AC091729.7 (CHLSN-AS1) expression as a prognostic biomarker for sinonasal squamous cell carcinoma
Beyond the preview
Go deeper on CHLSN antisense RNA 1 (CHLSN-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHLSN antisense RNA 1 (CHLSN-AS1).